

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re United States Patent Application (35 USC 371) of:

Applicant(s): **Andreas MAHN, et al.**

Application No.: **10/500,264**

Date Filed: **June 18, 2004**

Title: **METHOD OF INCREASING THE
TRANSGENE-CODED
BIOMOLECULE CONTENT IN
ORGANISMS**

Atty. Docket No.: **4121-168**


Conf. No.: **9836**

Examiner: **Unassigned**

Customer No.: **23448**

EXPRESS MAIL CERTIFICATE (37 CFR 1.10)

I hereby certify that this response is being filed in the United States Patent and Trademark Office, by Express Mail addressed to Mail Stop PCT, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on December 27, 2005, in accordance with the requirements of 37 CFR 1.10.


Joanna Joslyn

December 27, 2005

Date

RESPONSE TO NOVEMBER 25, 2005 WITHDRAWAL OF PREVIOUSLY SENT NOTICE AND CORRECTED NOTICE IN U.S. PATENT APPLICATION NO. 10/500,264; REQUEST FOR CORRECTION OF USPTO RECORDS; SUBMISSION OF SEQUENCE LISTING IN COMPUTER READABLE FORM WITH STATEMENT UNDER 37 CFR 1.821-1.825; AND PRELIMINARY AMENDMENT

Mail Stop PCT
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

This responds to the November 25, 2005 Withdrawal of Previously Sent Notice and Corrected Notification in the above-identified application.

It was stated in the Notification that a copy of the Sequence Listing in computer readable form had previously been submitted in this application, but a review of the file of the application and USPTO PAIR records relating to the application indicate that no sequence listing has been earlier submitted. The USPTO is correspondingly requested to correct its records for this application.

Enclosed and submitted herewith are a computer readable diskette containing a sequence listing in compliance with 37 CFR 1.822 and 1.823, and appertaining statement and written sequence listing required under 37 CFR 1.821- 1.825.

Consistent with the foregoing, please preliminarily amend the specification of the application as set forth in Section I (Amendments to the Specification) hereof.

Remarks relating to such amendments and to the accompanying submission of sequence listing in written form and computer readable form, with a statement of identity, are set out in Section II (Remarks) hereof.